Objective: To determine standardized incidence estimates for HS in the United States.
Objective: To establish standardized overall and group-specific prevalence estimates for HS in the United States.
There are no population-based incidence studies of hidradenitis suppurativa (HS).
Clinical practices for hidradenitis suppurativa (HS) are rapidly evolving because of increased attention to HS in recent years and ongoing research on disease pathophysiology and optimal treatments.
Areas covered: A comprehensive literature search was conducted to identify published HS treatments using PubMed databases, in addition, ongoing studies were sought in clinicaltrials.gov.
Hidradenitis suppurativa is a chronic inflammatory disorder affecting hair follicles, with profoundly negative impact on patient quality of life.
Objective: To evaluate the efficacy and safety of adalimumab, an anti-tumor necrosis factor-α antibody, in patients with moderate to severe HS.
We aimed to review the most up-to-date information regarding the epidemiology, clinical presentation, diagnostic studies, pathogenesis, comorbidities and quality of life of patients with hidradenitis suppurativa.
Introduction: Hidradenitis suppurativa (HS) is a serious, debilitating, chronic inflammatory skin disease. Adalimumab is a fully human, immunoglobulin G1 monoclonal antibody specific for tumor necrosis factor-alpha...
It is challenging to estimate a true prevalence of hidradenitis suppurativa (HS) because it is underdiagnosed and misdiagnosed.